— Amicus Therapeutics (NASDAQ: FOLD) reported Q3 2019 loss of $0.24 per share, vs. a loss of $0.32 expected.
— Revenues grew 137% to $48.8 million, vs. $47.6 million expected.
— Global revenue for Galafold was $48.8 million.
— FY19 Galafold revenue is expected to be $170 million to $180 million.
Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a
PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the
With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,